2-methoxy-N-methyl-N-phenylacetamide | 70383-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methoxy-N-methyl-N-phenylacetamide
• 英文别名: methoxy-N-methylacetanilide
• CAS: 70383-12-9
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD03576123
• 分子量: 179.219
• InChiKey: SWUXCSNUHDRKFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲氧基乙酸 、 N-甲基苯胺 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以78%的产率得到2-methoxy-N-methyl-N-phenylacetamide
  参考文献：
  名称：

  Synthesis, physico-chemical properties and microsomal stability of compounds bearing aliphatic trifluoromethoxy group

  摘要：

  Effects of the trifluoromethoxy substituent on physico-chemical properties of compounds, such as kinetic solubility, lipophilicity and microsomal clearance, was studied in a series of aliphatic derivatives. It was found that kinetic solubility of the CF3O-containing compounds was comparable to that of analogs, i.e. compounds bearing CH3O and CF3 moieties. The CF3O-substituted compounds had higher lipophilicity as compared to methoxy analogues, and nearly the same like CF3-bearing compounds. Microsomal stability studies indicated that the trifluoromethoxy group typically decreased metabolic stability of the corresponding derivatives as compared to either CH3O- or CF3-substituted counterparts, except for N-alkoxy(sulfon)amide series.

  DOI：

  10.1016/j.jfluchem.2020.109461

文献信息

• 8-Hydroxyquinoline compounds and methods thereof
  申请人：Bursavich Matthew G.

  公开号：US20080269213A1

  公开（公告）日：2008-10-30

  The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.

  本发明涉及8-羟基喹啉化合物；包含一种8-羟基喹啉化合物的组合物；以及治疗或预防金属蛋白酶相关疾病的方法，例如关节炎、骨关节炎、恶性肿瘤、类风湿性关节炎、哮喘、慢性阻塞性肺病、动脉粥样硬化、年龄相关性黄斑变性、心肌梗死、角膜溃疡、眼表疾病、肝炎、主动脉瘤、肌腱炎、中枢神经系统疾病、异常伤口愈合、血管生成、再狭窄、肝硬化、多发性硬化症、肾小球肾炎、移植物抗宿主病、糖尿病、炎性肠病、休克、椎间盘退化、中风、骨质疏松或牙周疾病；或者包括向需要的哺乳动物施用有效剂量的8-羟基喹啉化合物。
• Withaferin compositions for prevention of aging
  申请人：Insilico Medicine, Inc.

  公开号：US10729703B2

  公开（公告）日：2020-08-04

  The present invention provides gero-protective pharmaceutical compositions and methods, the compositions being adapted to enhance at least one of cell survival and cell metabolism in a mammalian subject, the pharmaceutical compositions include at least two of Withaferin a or its structural analogs, coumestrol, ginsenoside, quinidine, silymarin, licochalcone a, lipoic acid and apigenin, in a pharmaceutically effective amount.

  本发明提供了具有零保护作用的药物组合物和方法，这些组合物适用于提高哺乳动物体内细胞存活率和细胞新陈代谢中的至少一种，药物组合物包括至少两种有效药用量的威化尔素a或其结构类似物、香豆素、人参皂苷、奎尼丁、水飞蓟素、甘草查耳酮a、硫辛酸和芹菜素。
• GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
  申请人：Glaxo Group Limited

  公开号：EP2121625A1

  公开（公告）日：2009-11-25
• Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic
  申请人：Gulati Anil

  公开号：US20080207763A1

  公开（公告）日：2008-08-28

  A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction.
• Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin
  申请人：Gulati Anil

  公开号：US20100173872A1

  公开（公告）日：2010-07-08

  A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.